Boston Scientific Sinks on Weak Quarterly Top-Line Guidance By

© Reuters.

© Reuters.

By Kim Khan – Medical device maker Boston Scientific (NYSE:) stumbled out of the gate Tuesday, with investors disappointed with guidance released this morning.

Shares fell 7.6% in morning trading.

Boston Scientific (NYSE:) said it still see fourth-quarter of 42 to 45 cents per share, in line with the consensus of 44 cents per share according to forecasts compiled by

But it sees revenue of about $2.9 billion, lower than consensus expectations of $2.93 billion. That would be a rise of about 13.4% from the year-ago period, near the lower end of its previous guidance of a rise of 13% to 15%.

Expectations had been high Boston Scientific’s upcoming earnings. In late December Cowen boosted its price target on shares to $52 from $47, saying that 2020 guidance should “fuel the bull case while leaving upside to the top- and bottom-line ranges.”

Before today’s drop, shares were up nearly 20% in the last three months.

The company reports earnings on Feb. 5.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link


Please enter your comment!
Please enter your name here